| Name: | Emtricitabine Carboxylic Acid Impurity |
| Catalogue No. | VL54002 |
| CAS No. | 1238210-10-0 |
| Molecular Formula | C8H8FN3O4S |
| Molecular Weight | 261.23 |
| Status | In-stock |
| IUPAC Name | (2R,5S)-5-(4-Amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)-1,3-oxathiolane-2-carboxylic Acid |
| Synonyms | Emtricitabine IP Impurity A |
| Appearance | Light brown powder |
| Description | Emtricitabine Carboxylic Acid Impurity (CAS No.1238210-10-0) or (2R,5S)-5-(4-Amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)-1,3-oxathiolane-2-carboxylic Acid. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for the use in combination therapy. |
| References | Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://doi.org/10.2165/00003495-200363220-00003. Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https:// |
